NCT01461824View on ClinicalTrials.gov

Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

July 31, 2016

Conditions
Weight GainDisorder of Bone Density and Structure, UnspecifiedUterine Bleeding
Interventions
DRUG

Depot medroxyprogesterone acetate (DMPA)

75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

All Listed Sponsors
collaborator

Society of Family Planning

OTHER

lead

Nationwide Children's Hospital

OTHER

NCT01461824 - Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects | Biotech Hunter | Biotech Hunter